B7-H6 as a Diagnostic Biomarker for Cervical Squamous Cell Carcinoma
- PMID: 34280008
- DOI: 10.1089/gtmb.2020.0313
B7-H6 as a Diagnostic Biomarker for Cervical Squamous Cell Carcinoma
Abstract
Background: B7-H6, a newly discovered member of the immunoglobulin superfamily, exerts antitumor effects by binding to NKP30 receptor on natural killer cells; it has important clinical implications. Cell surface ectodomain shedding of B7-H6 generates soluble B7-H6 (sB7-H6), which is highly expressed and serves as a valuable biomarker in multiple tumors, but the clinical significance and diagnostic value of B7-H6 in cervical squamous cell carcinoma (CSCC) remains unclear. Objective: To assess the expression and diagnostic value of B7-H6 in CSCC. Methods: In this study, 69 cervical specimens were analyzed for B7-H6 expression: 25 paired CSCC tissues were examined using quantitative real-time polymerase chain reaction, and 24 paraffin-embedded CSCC tissues and 20 normal tissues were analyzed immunohistochemically. Furthermore, plasma samples from 30 CSCC patients and 24 healthy controls were examined using ELISA. Results: B7-H6 mRNA and protein levels were significantly higher in CSCC tissues than in adjacent normal cervical tissues (p < 0.05). Immunohistochemical analysis revealed that high B7-H6 expression correlated with stromal invasion (p = 0.043), lymphovascular space involvement (p = 0.005), lymph node metastasis (p = 0.019), and International Federation of Gynecology and Obstetrics (FIGO) stage (p = 0.002). Moreover, ELISA results demonstrated that the sB7-H6 concentration in peripheral blood was higher in CSCC patients than in healthy controls (p < 0.0001). Notably, at the optimal cutoff point of 0.076 ng/mL, sB7-H6 showed 93.3% sensitivity and 62.5% specificity in the discrimination of CSCC patients from healthy controls. Conclusions: B7-H6 mRNA and protein levels are markedly increased in CSCC tissues and peripheral blood samples, and the B7-H6 level can be used as a biomarker for predicting the severity of CSCC disease and discriminating CSCC patients from healthy controls.
Keywords: B7-H6; NKP30; cervical squamous cell carcinoma; diagnostic biomarker; soluble B7-H6.
Similar articles
-
Harnessing B7-H6 for Anticancer Immunotherapy: Expression, Pathways, and Therapeutic Strategies.Int J Mol Sci. 2024 Sep 25;25(19):10326. doi: 10.3390/ijms251910326. Int J Mol Sci. 2024. PMID: 39408655 Free PMC article. Review.
-
Secreted Ligands of the NK Cell Receptor NKp30: B7-H6 Is in Contrast to BAG6 Only Marginally Released via Extracellular Vesicles.Int J Mol Sci. 2021 Feb 22;22(4):2189. doi: 10.3390/ijms22042189. Int J Mol Sci. 2021. PMID: 33671836 Free PMC article.
-
Induction of B7-H6, a ligand for the natural killer cell-activating receptor NKp30, in inflammatory conditions.Blood. 2013 Jul 18;122(3):394-404. doi: 10.1182/blood-2013-01-481705. Epub 2013 May 17. Blood. 2013. PMID: 23687088 Clinical Trial.
-
B7-H6, an immunoligand for the natural killer cell activating receptor NKp30, reveals inhibitory effects on cell proliferation and migration, but not apoptosis, in cervical cancer derived-cell lines.BMC Cancer. 2020 Nov 10;20(1):1083. doi: 10.1186/s12885-020-07608-4. BMC Cancer. 2020. PMID: 33172426 Free PMC article.
-
[Research Advances of A New Co-stimulatory Molecule-B7 Homolog 6--Review].Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2016 Feb;24(1):295-8. doi: 10.7534/j.issn.1009-2137.2016.01.057. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2016. PMID: 26913440 Review. Chinese.
Cited by
-
Harnessing B7-H6 for Anticancer Immunotherapy: Expression, Pathways, and Therapeutic Strategies.Int J Mol Sci. 2024 Sep 25;25(19):10326. doi: 10.3390/ijms251910326. Int J Mol Sci. 2024. PMID: 39408655 Free PMC article. Review.
-
Killer instincts: natural killer cells as multifactorial cancer immunotherapy.Front Immunol. 2023 Nov 28;14:1269614. doi: 10.3389/fimmu.2023.1269614. eCollection 2023. Front Immunol. 2023. PMID: 38090565 Free PMC article. Review.
-
Identification of Plasma Biomarkers for B7 Family Members Associated With Primary Sjögren's Syndrome.Immun Inflamm Dis. 2025 Aug;13(8):e70250. doi: 10.1002/iid3.70250. Immun Inflamm Dis. 2025. PMID: 40844039 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases